Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 278

1.

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.

Herrlinger KR, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke JD, Boerner N, Kueppers B, Emmrich J, Mescheder A, Schwertschlag U, Shapiro M, Stange EF.

Am J Gastroenterol. 2006 Apr;101(4):793-7.

PMID:
16635225
[PubMed - indexed for MEDLINE]
2.

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group.

Aliment Pharmacol Ther. 2002 Mar;16(3):399-406.

PMID:
11876692
[PubMed - indexed for MEDLINE]
Free Article
3.

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.

Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B.

Gastroenterology. 2000 Dec;119(6):1473-82.

PMID:
11113068
[PubMed - indexed for MEDLINE]
4.

Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.

Escher JC; European Collaborative Research Group on Budesonide in Paediatric IBD.

Eur J Gastroenterol Hepatol. 2004 Jan;16(1):47-54.

PMID:
15095852
[PubMed - indexed for MEDLINE]
5.

A comparison of budesonide with prednisolone for active Crohn's disease.

Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H, et al.

N Engl J Med. 1994 Sep 29;331(13):842-5.

PMID:
8078530
[PubMed - indexed for MEDLINE]
Free Article
6.

Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.

Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G.

Dig Liver Dis. 2003 Sep;35(9):619-27.

PMID:
14563183
[PubMed - indexed for MEDLINE]
7.

Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M; Onercept Study Group.

Clin Gastroenterol Hepatol. 2006 Jul;4(7):888-93. Epub 2006 Jun 22.

PMID:
16797249
[PubMed - indexed for MEDLINE]
8.

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.

Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG.

Gut. 1997 Aug;41(2):209-14.

PMID:
9301500
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.

Gastroenterology. 2007 May;132(5):1672-83. Epub 2007 Mar 21.

PMID:
17484865
[PubMed - indexed for MEDLINE]
10.

Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.

Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bär U, Weber A, Gierend M, Ewe K, Schölmerich J.

Eur J Gastroenterol Hepatol. 1996 Sep;8(9):905-9.

PMID:
8889459
[PubMed - indexed for MEDLINE]
11.

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.

Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84.

PMID:
15709987
[PubMed - indexed for MEDLINE]
Free Article
12.

Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.

Levine A, Kori M, Dinari G, Broide E, Shaoul R, Yerushalmi B, On A, Bujanover Y, Pröls M, Greinwald R; Israeli Pediatric Budesonide Study Group.

Inflamm Bowel Dis. 2009 Jul;15(7):1055-61. doi: 10.1002/ibd.20881.

PMID:
19229988
[PubMed - indexed for MEDLINE]
13.

A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.

Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H.

Am J Gastroenterol. 2008 Sep;103(9):2284-92. doi: 10.1111/j.1572-0241.2008.02024.x. Epub 2008 Jul 30.

PMID:
18671816
[PubMed - indexed for MEDLINE]
14.

Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group).

Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, Scheurlen C, Koop I, Pudel V, Carr L.

Scand J Gastroenterol. 1996 Aug;31(8):778-85.

PMID:
8858747
[PubMed - indexed for MEDLINE]
15.

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soulé JC, Gendre JP, Galmiche JP, Danne O, Cadiot G, Lamouliatte H, Belaïche J, Mary JY.

Gastroenterology. 1996 Mar;110(3):688-93.

PMID:
8608877
[PubMed - indexed for MEDLINE]
16.

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW.

N Engl J Med. 2000 Jun 1;342(22):1627-32.

PMID:
10833208
[PubMed - indexed for MEDLINE]
Free Article
17.

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T.

N Engl J Med. 1994 Sep 29;331(13):836-41.

PMID:
8078529
[PubMed - indexed for MEDLINE]
Free Article
18.

Anti-interleukin-12 antibody for active Crohn's disease.

Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W; Anti-IL-12 Crohn's Disease Study Group.

N Engl J Med. 2004 Nov 11;351(20):2069-79. Erratum in: N Engl J Med. 2005 Mar 24;352(12):1276. Yang, Zhiqiong [added].

PMID:
15537905
[PubMed - indexed for MEDLINE]
Free Article
19.

A controlled double blind study of azathioprine in the management of Crohn's disease.

Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R.

Gut. 1995 Nov;37(5):674-8.

PMID:
8549944
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.

Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, Fife R, Korn J, Simms R, Tesser J, Hillson J, Caldwell J, Schnitzer T, Lyons D, Schwertschlag U.

Arthritis Res. 2001;3(4):247-52. Epub 2001 Apr 10.

PMID:
11438043
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk